title: Eosinophils in acute renal allograft rejection.
abstract: Tissue eosinophils have been previously implicated in allograft rejection and graft loss. The aim of this study was to evaluate the role of eosinophils in acute renal allograft rejection. Data from 71 patients with 114 renal biopsies with acute allograft rejection were compared with those from 26 controls. The median tissue eosinophil density (0.4-1.1 eosinophils per micron2 x 10(6)) and the median peripheral blood eosinophilia (1.5-3.0%) in all grades of acute interstitial rejection and in acute vascular rejection were higher than in controls (0.0 eosinophils per micron2 x 10(6), p < 0.0023, and 0.9%, p < 0.035). In all grades of rejection, 36-54% of biopsies had tissue eosinophil density > or = 1 eosinophil per micron2 x 10(6), and 20-36% of patients had peripheral blood eosinophilia > or = 4%, compared with 0% and 4%, respectively, in controls (p < 0.000 and p = 0.0245). The sensitivity, specificity and overall accuracy of predicting acute rejection with tissue eosinophil density > or = 1 eosinophil per micron2 x 10(6) is 41%, 100% and 52%, and for peripheral blood eosinophila > or = 4% is 23%, 96% and 40%, respectively. The median tissue eosinophil density in acute rejection with graft loss was 1.9 eosinophils per micron2 x 10(6) compared to 0.2 eosinophils per micron2 x 10(6) in acute rejection without graft loss (p = 0.014), and 67% of acute rejection with graft loss had tissue eosinophil density > or = 1 eosinophil per micron2 x 10(6) compared with 28% of acute rejection without graft loss (p = 0.028).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Nephrology Unit, John Hunter Hospital, Newcastle, NSW, Australia.
authors.forename: W
authors.initials: W
authors.lastname: Hongwei
authors.forename: R S
authors.initials: RS
authors.lastname: Nanra
authors.forename: A
authors.initials: A
authors.lastname: Stein
authors.forename: L
authors.initials: L
authors.lastname: Avis
authors.forename: A
authors.initials: A
authors.lastname: Price
authors.forename: A D
authors.initials: AD
authors.lastname: Hibberd
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001706:Biopsy; D002648:Child; D004802:Eosinophilia / Q000209:etiology / Q000473:pathology*; D004804:Eosinophils / Q000502:physiology*; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000473:pathology* / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy; D015848:Interleukin-5 / Q000502:physiology; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011379:Prognosis; D012680:Sensitivity and Specificity; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology
chemical_list: D000305:Adrenal Cortex Hormones; D015848:Interleukin-5; D016853:Muromonab-CD3